Sitagliptin and Metformin Explained: How Sitomni-M Works

Metformin belongs to the biguanide class and is one of the most widely used oral medicines in diabetes care worldwide. Its origins trace back to plant chemistry studied long before modern diabetes clinics existed, and it has been in mainstream clinical use for decades.

Its main action is on the liver. Between meals and through the night, the liver manufactures and releases glucose through a process called gluconeogenesis. In type 2 diabetes this process runs harder than it should, which is one reason fasting readings are high. Metformin reduces that output.

A second action is on peripheral tissues, mainly muscle, where it improves the response to insulin so glucose moves out of the blood more readily. It also slows glucose absorption from the gut to a degree.

Because metformin does not stimulate the pancreas to pour out insulin, it does not usually cause low blood sugar when taken alone. That single property is a large part of why it remains a first choice for so many patients.

Sitagliptin belongs to a newer group known as DPP-4 inhibitors, or gliptins. Understanding it means starting with the incretin effect.

When food reaches the gut, cells in the intestinal lining release hormones called GLP-1 and GIP. These incretins prompt the pancreas to release insulin and tell the alpha cells to release less glucagon, the hormone that raises blood sugar. This is why glucose taken by mouth produces a bigger insulin response than the same amount given into a vein.

The catch is that an enzyme called dipeptidyl peptidase-4 breaks these hormones down within a few minutes. Sitagliptin blocks that enzyme, so the incretin signal persists longer after every meal.

The key feature is that this action is glucose dependent. The insulin push happens when glucose is elevated and fades when it is not, which is why gliptins on their own are not typical causes of hypoglycaemia. They are also generally weight neutral, which matters to many patients.

It helps to think of oral diabetes medicines as answering different questions.

Within the gliptin class, molecules differ mainly in how they are cleared from the body, which affects dosing in kidney or liver impairment, and in their interaction profiles. Choosing between them is a clinical decision that depends on the individual patient, not on a general ranking.

Once a doctor has decided a patient needs two molecules, there are two ways to deliver them: two separate tablets, or one tablet containing both. Fixed-dose combinations such as Sitomni-M 50/500 exist for practical reasons.

The trade-off is flexibility. With separate tablets a doctor can fine-tune each molecule independently. That is exactly why fixed-dose combinations come in several strengths, and why moving between them is a decision for the doctor rather than the patient.

Knowing the classes is useful for three reasons. It explains why your doctor asks about kidney function, since metformin is cleared by the kidneys. It explains why stomach upset is common early on, since that comes from the metformin side. And it explains why low blood sugar is not the usual pattern with this pair unless another medicine such as insulin or a sulfonylurea is added.

It also explains why the tablet is prescription only. Choosing the right class, the right strength and the right combination for a specific person needs training and test results.

Use this knowledge to ask better questions at your next appointment rather than to adjust anything yourself. This article is for general information only and is not a substitute for advice from a registered medical practitioner.